NASDAQ:DMAC DiaMedica Therapeutics Q3 2026 Earnings Date & Estimates $7.76 -0.06 (-0.72%) As of 01:44 PM Eastern This is a fair market value price provided by Massive. Learn more. DiaMedica Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from DiaMedica Therapeutics in Q3 2026DiaMedica Therapeutics is expected to post earnings of -$0.20 per share on revenue of $13.50 million. In the same quarter a year earlier DiaMedica Therapeutics reported -$0.17 per share. DiaMedica Therapeutics last reported on August 10, 2026, posting -$0.19 per share and beating the -$0.2009 consensus estimate. DiaMedica Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.20Expected Revenue$13.50 millionPrior-Year EPS-$0.17Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.19 (Beat by +$0.0109)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report DiaMedica Therapeutics Q3 2026 Earnings FAQ When does DiaMedica Therapeutics report Q3 2026 earnings? DiaMedica Therapeutics (NASDAQ:DMAC) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is DiaMedica Therapeutics' Q3 2026 earnings call? DiaMedica Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for DiaMedica Therapeutics? Analysts expect DiaMedica Therapeutics to post earnings of -$0.20 per share for Q3 2026. How much revenue is DiaMedica Therapeutics expected to report? The consensus revenue estimate for DiaMedica Therapeutics is $13.50 million for Q3 2026. DiaMedica Therapeutics Earnings HeadlinesDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsSeptember 30, 2026 | businesswire.comDiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 2, 2026 | finance.yahoo.com5 secondsBill Poulos put together a Top 10 Stocks to Buy This Quarter report, explaining each pick in plain English. It normally sells for 29.97, but it's available free for a limited time, before next quarter's list replaces it. The download takes about five seconds.October 14 at 1:00 AM | Profits Run (Ad)DiaMedica (DMAC) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comDiaMedica Therapeutics Inc. (DMAC) Q2 FY2026 earnings call transcriptAugust 12, 2026 | finance.yahoo.comDiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...August 11, 2026 | finance.yahoo.comSee More DiaMedica Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DiaMedica Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your email. Email Address About DiaMedica TherapeuticsDiaMedica Therapeutics (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options. Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury. The product remains investigational and has not been approved for commercial use. DiaMedica is based in Minneapolis, Minnesota, and conducts its clinical and development activities through research collaborations and clinical studies. The company’s leadership has included Rick Pauls as president and chief executive officer. Its programs have primarily targeted patients in the United States and other regions where clinical trials are conducted.View DiaMedica Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
